IPO Year: 2021
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2025 | $5.00 | Buy | Laidlaw |
| 10/7/2022 | $7.50 | Equal-Weight | Morgan Stanley |
Fastest customizable press release news feed in the world
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform commit
Access the "What This Means" segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company's recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell t
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. "Our team has continued to advance SENTI-202's clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). The Phase 1 clinical trial of SENTI-202 is enrolling adult patients with rel
SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now ava
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the BioScience Forum being held July 23, 2025 in San Carlos, CA. Details of the presentation are as follows: Title: Using Logic Gated CARs to Drive Cancer TreatmentSpeaker: Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti BioDate and Time: Wednesday, July 23rd at 6:00 PM PT The BioScience Forum is a non-profit educational forum
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures. Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer recently participated in Nasdaq's Amplify Spotlight Series. As part of the segment, Dr. Lu provided a corporate overview and highlighted how Senti is leveraging its proprietary Gene Circuit platform to develop next-generation cell and gene therapies for the treatment of challenging liquid and solid tumor indications. T
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference being held June 23-26, 2025 in Houston, TX. Details of the presentation are as follows: Session: Building with BiologyTitle: Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated CellsPresenter: Timothy Lu, MD, PhD, Co-Founder and CEO of Senti BiosciencesDate and Time: Tuesday, June 24, 20
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases Virtual Investor "What This Means" segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00
Morgan Stanley initiated coverage of Senti Bio with a rating of Equal-Weight and set a new price target of $7.50
10-Q - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
8-K - Senti Biosciences, Inc. (0001854270) (Filer)
SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SCHEDULE 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
4 - Senti Biosciences, Inc. (0001854270) (Issuer)
3 - Senti Biosciences, Inc. (0001854270) (Issuer)
Live Leadership Updates
Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor
This live feed shows all institutional transactions in real time.
SC 13D/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G/A - Senti Biosciences, Inc. (0001854270) (Subject)
SC 13G - Senti Biosciences, Inc. (0001854270) (Subject)
Live finance-specific insights
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025. Details for the presentation are as follows: Date/Time: Tuesday, August 19, 2025 at 2:20 PM ET Presenter: Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive OfficerRegistration Link: HERE About Webull Financial Webull Financial is a leading online brokerage platform commit
Access the "What This Means" segment here SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it participated in a Virtual Investor "What This Means" segment. For the segment, Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti, discussed the Company's recently announced recommended Phase 2 dose selection for its potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell t
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the second quarter of 2025 and provided a summary of recent pipeline and corporate highlights. "Our team has continued to advance SENTI-202's clinical development. We have now completed dose finding and have confirmed the recommended Phase 2 dose (RP2D), which is an important step in our Phase 1 study. We are currently in the dose expansion phase, enrolling additional patients with relapsed/refractory AML
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced it has confirmed the recommended Phase 2 dose (RP2D) in its Phase 1 study of SENTI-202, the Company's potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, in development for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (AML). The Phase 1 clinical trial of SENTI-202 is enrolling adult patients with rel
SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now ava
SOUTH SAN FRANCISCO, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the BioScience Forum being held July 23, 2025 in San Carlos, CA. Details of the presentation are as follows: Title: Using Logic Gated CARs to Drive Cancer TreatmentSpeaker: Kanya Rajangam, M.D., Ph.D., President, Head of Research & Development and Chief Medical Officer of Senti BioDate and Time: Wednesday, July 23rd at 6:00 PM PT The BioScience Forum is a non-profit educational forum
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Bryan Baum to its Board of Directors. Mr. Baum is a serial entrepreneur and investor and is the Co-Founder and Managing Partner of K5 Global. His portfolio includes category-defining companies such as SpaceX, xAI, Anduril, Canva, Databricks, Grafana, OpenAI, and others. He has also founded and successfully exited multiple ventures. Timothy Lu, M.D., Ph.D., Senti Bio's Co-Founder
Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer recently participated in Nasdaq's Amplify Spotlight Series. As part of the segment, Dr. Lu provided a corporate overview and highlighted how Senti is leveraging its proprietary Gene Circuit platform to develop next-generation cell and gene therapies for the treatment of challenging liquid and solid tumor indications. T
SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference being held June 23-26, 2025 in Houston, TX. Details of the presentation are as follows: Session: Building with BiologyTitle: Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated CellsPresenter: Timothy Lu, MD, PhD, Co-Founder and CEO of Senti BiosciencesDate and Time: Tuesday, June 24, 20
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases Virtual Investor "What This Means" segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-